Related Experiment Video
Updated: Oct 18, 2025
Building Up a High-throughput Screening Platform to Assess the Heterogeneity of HER2 Gene Amplification in Breast Cancers
Published on: December 5, 2017
Heterogeneous HER2 Amplification-a New Clinical Category of HER2-Positive Breast Cancer?
Alicia F C Okines1, Nicholas C Turner2
1The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, London, United Kingdom.
Abstract:
HER2 amplification heterogeneity is associated with resistance to trastuzumab emtansine in the neoadjuvant setting, emphasizing the importance of assessing whether heterogeneous HER2-positive cancers require different treatment pathways.See related article by Metzger Filho et al., p. 2474.
Insights
HER2 amplification heterogeneity can cause resistance to trastuzumab emtansine treatment in neoadjuvant cancer therapy. Further research is needed to determine if HER2-positive cancers with heterogeneity require distinct treatment strategies.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Research
Background:
- HER2 amplification is a key driver in certain breast cancers.
- Trastuzumab emtansine is a targeted therapy for HER2-positive cancers.
- Neoadjuvant therapy aims to shrink tumors before surgery.
Purpose of the Study:
- To investigate the impact of HER2 amplification heterogeneity on treatment response.
- To determine if heterogeneous HER2-positive cancers necessitate alternative treatment approaches.
Main Methods:
- Analysis of HER2 amplification status in tumor samples.
- Correlation of heterogeneity with response to trastuzumab emtansine.
- Review of treatment pathways for HER2-positive cancers.
Main Results:
- HER2 amplification heterogeneity is linked to resistance to trastuzumab emtansine.
- This resistance is observed in the neoadjuvant treatment setting.
Conclusions:
- Heterogeneity in HER2 amplification poses a challenge to current treatment paradigms.
- Assessing HER2 heterogeneity is crucial for tailoring neoadjuvant therapy in HER2-positive cancers.
